Please provide your email address to receive an email when new articles are posted on . There are limited numbers of FDA-approved medications to treat alcohol and substance use disorders. Preclinical ...

Joshua Kaufman, MD, medical director of Behavioral Health and Medical Integration at Capital District Physicians' Health Plan, discusses the bidirectional relationship between schizophrenia and ...

Preclinical studies in animals have already shown that GLP-1 drugs can reduce reward-seeking behavior. Early clinical work in humans has begun to hint at similar effects. A randomized trial of ...

In 524,817 adults with T2D, GLP-1 RA use was associated with lower incident alcohol, cocaine, cannabis, opioid, and nicotine ...

Large veteran study links GLP-1 diabetes drugs to lower risk of developing substance use disorders and fewer overdoses, hospitalizations and drug-related deaths.

The effect was seen across a wide variety of addictive and habit-forming substances, including cocaine, opioids, alcohol, ...

The COVID-19 pandemic has created both short-term and long-term negative consequences for behavioral health outcomes. The National Academies of Sciences, Engineering, and Medicine's Forum on Mental ...

Substance use disorders, such as alcohol use disorder, were found to be more prevalent among survivors of specific cancer types, according to research. Survivors of certain types of cancer have a ...

Polysubstance use disorder is a mental health condition in which someone uses more than one substance at the same time or within a short period of time, despite a pattern of negative effects.

Substance use disorders (SUDs) in oncology populations represent a significant yet underrecognized challenge, with prior research suggesting that up to 27 percent of cancer patients meet criteria for ...

Substance use and substance use disorder differ by the frequency of use and the effect on a person’s life. Substance use disorder is a mental health condition. Substance use refers to using both legal ...